Giant Fold Gastritis Induced by Epoprostenol Infusion in Patients With Pulmonary Arterial Hypertension

被引：3

作者：

Miura, Yohei ^{[1
]}

Kataoka, Masaharu ^{[3
]}

Chiba, Tomohiro ^{[2
]}

Inami, Takumi ^{[1
]}

Yoshino, Hideaki ^{[1
]}

Satoh, Toru ^{[1
]}

机构：

[1] Kyorin Univ, Sch Med, Dept Internal Med 2, Div Cardiol, Tokyo, Japan

[2] Kyorin Univ, Sch Med, Dept Pathol, Tokyo, Japan

[3] Keio Univ, Sch Med, Dept Cardiol, Tokyo, Japan

来源：

CIRCULATION JOURNAL | 2018年 / 82卷 / 10期

关键词：

Epoprostenol; Giant fold gastritis; Pulmonary arterial hypertension; Stomach barium examination; THERAPY;

D O I：

10.1253/circj.CJ-18-0349

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Epoprostenol infusion is the strongest and most convincing therapeutic strategy for severe pulmonary arterial hypertension (PAH). This study investigated the gastrointestinal side effects of epoprostenol. Methods and Results: The study group of 12 patients treated with epoprostenol (epoprostenol group) and 4 patients without epoprostenol (control group) underwent stomach barium examination, which revealed that the prevalence of giant fold gastritis was significantly higher in the patients treated with epoprostenol (75% in epoprostenol group vs. 0% in control group; P=0.019). Conclusions: Giant fold gastritis may be an important side effect of epoprostenol infusion.

引用

页码：2676 / 2677

页数：2

共 50 条

[11] Epoprostenol-associated ascites in pulmonary arterial hypertension
Schoenberg, Noah C.
Ruopp, Nicole F.
Parikh, Raj D.
Farber, Harrison W.
PULMONARY CIRCULATION, 2022, 12 (02)
[12] Epoprostenol (Veletri®, Caripul®): A Review of Its Use in Patients with Pulmonary Arterial Hypertension
Sarah L. Greig
Lesley J. Scott
Greg L. Plosker
American Journal of Cardiovascular Drugs, 2014, 14 : 463 - 470
[13] Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with Pulmonary Arterial Hypertension (EPITOME4)
Tamura, Yuichi
Ono, Tomohiko
Fukuda, Keiichi
Satoh, Toru
Sasayama, Shigetake
ADVANCES IN THERAPY, 2013, 30 (05) : 459 - 471
[14] Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol
Rossi, Rosario
Coppi, Francesca
Sgura, Fabio
Monopoli, Daniel
Boriani, Giuseppe
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2018, 49 : 147 - 151
[15] Longterm Survival Among Patients with Scleroderma-associated Pulmonary Arterial Hypertension Treated with Intravenous Epoprostenol
Badesch, David B.
McGoon, Michael D.
Barst, Robin J.
Tapson, Victor F.
Rubin, Lewis J.
Wigley, Fredrick M.
Kral, Kenneth M.
Raphiou, Ibrahim H.
Crater, Glenn D.
JOURNAL OF RHEUMATOLOGY, 2009, 36 (10) : 2244 - 2249
[16] Epoprostenol sodium for treatment of pulmonary arterial hypertension
Saito, Yukihiro
Nakamura, Kazufumi
Akagi, Satoshi
Sarashina, Toshihiro
Ejiri, Kentaro
Miura, Aya
Ogawa, Aiko
Matsubara, Hiromi
Ito, Hiroshi
VASCULAR HEALTH AND RISK MANAGEMENT, 2015, 11 : 265 - 270
[17] Hemodynamics and Epoprostenol Use Are Associated With Thrombocytopenia in Pulmonary Arterial Hypertension
Chin, Kelly M.
Channick, Richard N.
de Lemos, James A.
Kim, Nick H.
Torres, Fernando
Rubin, Lewis J.
CHEST, 2009, 135 (01) : 130 - 136
[18] Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension
Simonneau, Gerald
Rubin, Lewis J.
Galie, Nazzareno
Barst, Robyn J.
Fleming, Thomas R.
Frost, Adaani
Engel, Peter
Kramer, Mordechai R.
Serdarevic-Pehar, Marjana
Layton, Gary R.
Sitbon, Olivier
Badesch, David B.
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2014, 33 (07) : 689 - 697
[19] Intravenous epoprostenol therapy in the treatment of pulmonary arterial hypertension in Singapore
Choo, Jack
Yap, Jonathan
Ismail, Aidila
Hon, Jin Shing
Ruan, Wen
Low, Andrea
Lim, Soo Teik
Tan, Ju Le
ANNALS ACADEMY OF MEDICINE SINGAPORE, 2024, 53 (10) : 627 - 631
[20] How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?
Barst, R.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 : 23 - 32

← 1 2 3 4 5 →